Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

Korábbi kezelés

• Patient is enrolled on a clinical trial with investigational post-transplant medications. Note: trials involving defibrotide, post-transplant cyclophosphamide, and Lactobacillus plantarum are permitted. Other trials involving investigational medications that aren't leukemia or GVHD-directed may also be permitted after consultation with the overall PI.
• Concomitant use of coumarin-derived anticoagulants or valproic acid.
  • -

Más betegség

• Patient has a known allergy to azacitidine or vorinostat.

Laborértékek

• Patient has a planned administration of non-protocol chemotherapy, radiation therapy, donor leukocyte infusion, or immunotherapy during the planned study period.

Egyéb

• Patient has chronic myelogenous leukemia.

• Patient is 1 year to 21 years of age.
• Patient has a diagnosis of AML, MDS, MDS/AML, MPAL, or JMML. Note: patients are allowed to have received a HMA or HDACi prior to undergoing alloHCT.
• Patient has undergone allogeneic hematopoietic cell transplantation (no restrictions on conditioning regimen, donor or stem cell source, or GVHD prophylaxis regimen).
• Patient and/or parent(s) or legal guardian(s) are capable of understanding the study, including potential benefits and risks, and sign written informed consent. Age-appropriate assent will be obtained.
• Female patient of childbearing potential has a negative screening pregnancy test (urine or serum, as per local institutional standard).
• Female patient with infant(s) agrees not to breastfeed her infant(s) while on study.
• Patient of child-bearing potential (male and female) agrees to use effective method of contraception during the study.